Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases

Urology

Volumn 63, Issue 2, 2004, Pages 321-326

  Petrioli, Roberto ^b   Rossi, Stefania ^b   Caniggia, Mario ^b   Pozzessere, Daniele ^b   Messinese, Simona ^b   Sabatino, Marianna ^b   Marsili, Stefania ^b   Correale, Pierpaolo ^b   Salvestrini, Francesco ^b   Manganelli, Antonio ^b   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN; BIOCHEMICAL MARKER; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CREATININE; EPIRUBICIN; GONADORELIN ANTAGONIST; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CALCIUM URINE LEVEL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DATA ANALYSIS; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; URINALYSIS;

EID: 10744221138     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.09.044     Document Type: Article

References (31)

1. Maximum androgen blockade in advanced prostate cancer an overview of the randomised trials . Lancet. 355:2000;1491-1498.
2. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 52:2002;154-179.
3. Francini G., Petrioli R., Manganelli A., et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 67:1993;1430-1436.
4. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative end points . J Clin Oncol. 14:1996;1756-1764.
5. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer a final report of CALGB 9780 . J Clin Oncol. 19:2001;2509-2516.
6. Petrioli R., Fiaschi A.I., Pozzessere D., et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer. 87:2002;720-725.
7. Petrioli R., Pozzessere D., Messinese S., et al. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer previously exposed to chemotherapy. Oncology. 64:2003;300-305.
8. Knox J.J., Moore M.J. Treatment of hormone refractory prostate cancer. Semin Urol Oncol. 19:2001;202-211.
9. Francini G., Gonnelli S., Petrioli R., et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev. 2:1993;125-129.
10. de la Piedra C., Castro-Errecaborde N.-A., Traba M.L., et al. Bone remodeling makers in the detection of bone metastases in prostate cancer. Clin Chim Acta. 331:2003;45-53.
11. Tamada T., Sone T., Tomomitsu T., et al. Biochemical markers for the detection of bone metastasis in patients with prostate cancer diagnostic efficacy and the effect of hormonal therapy . J Bone Miner Metab. 19:2001;45-51.
12. Francini G., Petrioli R., Gonnelli S., et al. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer. 92:2001;1468-1474.
13. Manni A., Bartholomew M., Caplan R., et al. Androgen priming and chemotherapy in advanced prostate cancer evaluation of determinants of clinical outcome . J Clin Oncol. 6:1988;1456-1466.
14. Ernst D.S., Hanson J., Venner P.M. Analysis of prognostic factors in men with metastatic prostate cancer. J Urol. 146:1991;372-376.
15. Fossa S.D., Dearnaley D.P., Law M., et al. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol. 3:1992;361-366.
16. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 61:1988;195-202.
17. Francini G., Gonnelli S., Petrioli R., et al. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol. 10:1992;591-598.
18. Kahn H.A., Sempos C.T. Statistical Methods in Epidemiology. 1989;Oxford University Press, Oxford.
19. Altman D.G. Practical Statistics for Medical Research. 1991;Chapman and Hall, New York.
20. Meikko J., Niemi S., Risteli L., et al. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 36:1990;1328-1332.
21. Percherstrorfer M., Zimmer-Roth I., Shilling T., et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 80:1995;97-103.
22. Hotte S.J., Winquist E.W., Stitt L., et al. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma . Cancer. 95:2002;506-512.
23. Akimoto S., Furuya Y., Akakura K., et al. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis comparison with the extent of disease (EOD) grade . Prostate. 38:1999;28-34.
24. Kylmälä T., Tammela T.L., Risteli L., et al. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 71:1995;1061-1064.
25. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer. 80:1997;1538-1545.
26. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 20:2002;3972-3982.
27. Deftos L.J., Nakada S., Burton D.W., et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology. 48:1996;58-62.
28. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 17:1999;948-957.
29. Taylor C.D., Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 11:1993;2167-2172.
30. Chodak G.W., Vogelzang N.J., Caplan R.J., et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA. 265:1991;618-621.
31. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 21:2003;1232-1237.